Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial.
In a double-blind investigation N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was checked versus a reference substance (solvent of COP) on volunteers affected by ischemic heart disease with persistent ventricular premature beats (VPB). COP was able to reduce VPB by 50--100% in 85% of the volunteers treated with this drug. This fact and the virtual absence of side-effects of COP lead the authors to the conclusion that COP merits more extensive investigations in this field in view of its clinical employment alone or in association with specific antiarrhythmic agents.
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications*; D003401:Creatine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
C100173:creatinol phosphate; D003401:Creatine